U.S. markets closed

InnoCan Pharma Corporation (INNO.CN)

Canadian Sec - Canadian Sec Real Time Price. Currency in CAD
Add to watchlist
0.1800+0.0100 (+5.88%)
At close: 1:55PM EDT
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.1700
Open0.1800
Bid0.1750 x N/A
Ask0.1800 x N/A
Day's Range0.1700 - 0.1800
52 Week Range0.0500 - 0.4000
Volume50,500
Avg. Volume125,350
Market Cap31.562M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.0260
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Innocan Phrama Completes Successful Cosmetic Clinical Studies Demonstrating the Efficacy of Its SHIR(TM) CBD Premium Facial Serum on Skin Hydration
      Newsfile

      Innocan Phrama Completes Successful Cosmetic Clinical Studies Demonstrating the Efficacy of Its SHIR(TM) CBD Premium Facial Serum on Skin Hydration

      Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - September 15, 2020) -   Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the "Company" or "Innocan"), is pleased to announce today, that it has completed a cosmetic clinical study examining the impact of its SHIR ™ Premium CBD Facial Serum containing 300 mg of cannabidiol ("CBD") (the "Serum") on skin hydration.Table 2To view an enhanced version of Table 2, please visit:https://orders.newsfilecorp.com/files/6922/63880_98aa5e38b4389924_002full.jpgThe study was conducted by an independent ...

    • Innocan Pharma to Amend Warrants Held by Tamar Technologies Ltd.
      Newsfile

      Innocan Pharma to Amend Warrants Held by Tamar Technologies Ltd.

      Toronto, Ontario--(Newsfile Corp. - September 14, 2020) - Innocan Pharma Corporation (CNSX: INNO) (FSE: IP4) (the "Company" or "Innocan"), announces that its board of directors has agreed to amend the terms of certain common share purchase warrants (the "Warrants") held by Tamar Innovest Ltd. (formerly, Solsken Ltd.) ("Tamar").The Warrants were issued by the Company on April 15, 2019 and consist of: (a) 13,981,916 Warrants at an exercise price of US $0.1252 expiring April 15, ...

    • Innocan Pharma Announces Publication of Enterprise Report by Mackie Research
      Newsfile

      Innocan Pharma Announces Publication of Enterprise Report by Mackie Research

      Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - September 3, 2020) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the "Company" or "Innocan"), is pleased to announce that Mackie Research Capital Corporation's institutional sales group has issued an updated Enterprise report on the Company. The Enterprise report provides valuable insight into companies that embody value-add for investors, have distinguished themselves among their peers and are bringing innovative and creative ideas into action. Mackie Research's ...